232 related articles for article (PubMed ID: 26148314)
1. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer.
Winters-Stone KM; Dieckmann N; Maddalozzo GF; Bennett JA; Ryan CW; Beer TM
Oncol Nurs Forum; 2015 Jul; 42(4):348-56. PubMed ID: 26148314
[TBL] [Abstract][Full Text] [Related]
2. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
3. Exercise Improves V˙O2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients.
Wall BA; GALVãO DA; Fatehee N; Taaffe DR; Spry N; Joseph D; Hebert JJ; Newton RU
Med Sci Sports Exerc; 2017 Aug; 49(8):1503-1510. PubMed ID: 28319589
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
5. Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy.
Newton RU; Jeffery E; Galvão DA; Peddle-McIntyre CJ; Spry N; Joseph D; Denham JW; Taaffe DR
BJU Int; 2018 Dec; 122(6):986-993. PubMed ID: 29750398
[TBL] [Abstract][Full Text] [Related]
6. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
[TBL] [Abstract][Full Text] [Related]
7. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.
Hvid T; Winding K; Rinnov A; Dejgaard T; Thomsen C; Iversen P; Brasso K; Mikines KJ; van Hall G; Lindegaard B; Solomon TP; Pedersen BK
Endocr Relat Cancer; 2013 Oct; 20(5):621-32. PubMed ID: 23744766
[TBL] [Abstract][Full Text] [Related]
8. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
9. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
10. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
11. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
12. Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy.
Harrington JM; Schwenke DC; Epstein DR
Oncol Nurs Forum; 2013 Sep; 40(5):E358-67. PubMed ID: 23989028
[TBL] [Abstract][Full Text] [Related]
13. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
14. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
15. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
Taaffe DR; Newton RU; Spry N; Joseph D; Chambers SK; Gardiner RA; Wall BA; Cormie P; Bolam KA; Galvão DA
Eur Urol; 2017 Aug; 72(2):293-299. PubMed ID: 28249801
[TBL] [Abstract][Full Text] [Related]
16. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.
Newton RU; Taaffe DR; Spry N; Gardiner RA; Levin G; Wall B; Joseph D; Chambers SK; Galvão DA
BMC Cancer; 2009 Jun; 9():210. PubMed ID: 19563641
[TBL] [Abstract][Full Text] [Related]
17. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.
Galvão DA; Spry N; Denham J; Taaffe DR; Cormie P; Joseph D; Lamb DS; Chambers SK; Newton RU
Eur Urol; 2014 May; 65(5):856-64. PubMed ID: 24113319
[TBL] [Abstract][Full Text] [Related]
18. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
[TBL] [Abstract][Full Text] [Related]
19. Resistance training and reduction of treatment side effects in prostate cancer patients.
Galvão DA; Nosaka K; Taaffe DR; Spry N; Kristjanson LJ; McGuigan MR; Suzuki K; Yamaya K; Newton RU
Med Sci Sports Exerc; 2006 Dec; 38(12):2045-52. PubMed ID: 17146309
[TBL] [Abstract][Full Text] [Related]
20. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
